CorMedix Inc (NASDAQ: CRMD) closed the day trading at $3.42 down -2.84% from the previous closing price of $3.52. In other words, the price has decreased by -$0.1000 from its previous closing price. On the day, 1216549 shares were traded. CRMD stock price reached its highest trading level at $3.4600 during the session, while it also had its lowest trading level at $3.0300.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of CRMD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.78 and its Current Ratio is at 6.97. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on August 10, 2023, initiated with a Outperform rating and assigned the stock a target price of $6.
On February 17, 2021, Needham started tracking the stock assigning a Buy rating and target price of $31.
On September 29, 2020, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.JMP Securities initiated its Mkt Outperform rating on September 29, 2020, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’23 when DUNTON ALAN W bought 3,000 shares for $3.30 per share. The transaction valued at 9,900 led to the insider holds 15,250 shares of the business.
DUNTON ALAN W bought 3,000 shares of CRMD for $10,350 on Dec 14 ’23. The Director now owns 12,250 shares after completing the transaction at $3.45 per share. On Nov 17 ’23, another insider, Mistry Erin, who serves as the Chief Commercial Officer of the company, bought 1,000 shares for $4.00 each. As a result, the insider paid 4,000 and bolstered with 4,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 188.04M and an Enterprise Value of 102.15M. Its current Enterprise Value per Revenue stands at 3.44k whereas that against EBITDA is -2.57.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.84, which has changed by -3.12% over the last 52 weeks, in comparison to a change of 32.97% over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $6.09, while it has fallen to a 52-week low of $2.57. The 50-Day Moving Average of the stock is 3.3512, while the 200-Day Moving Average is calculated to be 3.7903.
Shares Statistics:
Over the past 3-months, CRMD traded about 415.66K shares per day on average, while over the past 10 days, CRMD traded about 429.1k shares per day. A total of 54.94M shares are outstanding, with a floating share count of 53.71M. Insiders hold about 2.01% of the company’s shares, while institutions hold 33.94% stake in the company. Shares short for CRMD as of Feb 29, 2024 were 7.72M with a Short Ratio of 18.57, compared to 7.19M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.08% and a Short% of Float of 14.21%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.21, while EPS last year was -$0.2. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.26 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.83 and -$0.86 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.76, with 4 analysts recommending between -$0.34 and -$0.96.
Revenue Estimates
Based on 4 analysts’ estimates, the company’s revenue will be $17.03M in the next fiscal year. The high estimate is $31.73M and the low estimate is $6.2M. The average revenue growth estimate for next year is down -6,912.00% from the average revenue estimate for this year.
